Head to Head Contrast: Spark Therapeutics (NASDAQ:ONCE) and MeiraGTx (NASDAQ:MGTX)
Spark Therapeutics (NASDAQ:ONCE) and MeiraGTx (NASDAQ:MGTX) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their valuation, dividends, analyst recommendations, risk, earnings, profitability and institutional ownership.
Insider and Institutional Ownership
84.1% of Spark Therapeutics shares are owned by institutional investors. Comparatively, 35.5% of MeiraGTx shares are owned by institutional investors. 6.0% of Spark Therapeutics shares are owned by insiders. Comparatively, 17.4% of MeiraGTx shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
This table compares Spark Therapeutics and MeiraGTx’s top-line revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Spark Therapeutics||$64.72 million||59.81||-$78.82 million||($2.11)||-47.66|
Spark Therapeutics has higher revenue and earnings than MeiraGTx. Spark Therapeutics is trading at a lower price-to-earnings ratio than MeiraGTx, indicating that it is currently the more affordable of the two stocks.
Risk and Volatility
Spark Therapeutics has a beta of 2.07, indicating that its stock price is 107% more volatile than the S&P 500. Comparatively, MeiraGTx has a beta of 1.99, indicating that its stock price is 99% more volatile than the S&P 500.
This is a breakdown of current ratings for Spark Therapeutics and MeiraGTx, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Spark Therapeutics currently has a consensus price target of $90.75, suggesting a potential downside of 9.77%. MeiraGTx has a consensus price target of $35.00, suggesting a potential upside of 65.80%. Given MeiraGTx’s stronger consensus rating and higher possible upside, analysts plainly believe MeiraGTx is more favorable than Spark Therapeutics.
This table compares Spark Therapeutics and MeiraGTx’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Spark Therapeutics beats MeiraGTx on 7 of the 12 factors compared between the two stocks.
About Spark Therapeutics
Spark Therapeutics, Inc. focuses on the development of gene therapy products for patients suffering from debilitating genetic diseases. Its products include LUXTURNA (voretigene neparvovec) for the treatment of patients with confirmed biallelic RPE65 mutation-associated retinal dystrophy and viable retinal cells. The company's gene therapy product candidates comprise SPK-8011 and SPK-8016 for hemophilia; SPK-7001 for choroideremia; and SPK-9001 for hemophilia B. It is also developing other liver-directed gene therapies, including SPK-3006 for Pompe disease; and neurodegenerative disease product candidates to address Huntington's disease and others, as well as TPP1 deficiency, which is a form of Batten disease. The company's preclinical programs targets inherited retinal diseases, including Stargardt's disease. The company has collaboration agreement with Pfizer, Inc. for the development and commercialization of SPK-FIX product candidates in its gene therapy program for the treatment of hemophilia B. It also has licensing and commercialization agreement with Novartis to develop and commercialize voretigene neparvovec outside the United States. Spark Therapeutics, Inc. was founded in 2013 and is headquartered in Philadelphia, Pennsylvania.
MeiraGTx Holdings plc, a clinical-stage gene therapy company, focusing on developing treatments for patients living with serious diseases. The company develops various therapies for ocular diseases, including rare inherited blindness, as well as Xerostomia following radiation treatment for head and neck cancers; neurodegenerative diseases, such as amyothrophic lateral sclerosis; and Parkinson's diseases. Its programs in clinical development include Phase 1/2 clinical stage programs in Achromatopsia, X-Linked Retinitis Pigmentosa, RPE65-deficiency, and radiation-induced Xerostomia, as well as Parkinson's program. The company also focuses on initiating a clinical program in xerostomia related to Sjogren's syndrome and have preclinical programs in neurodegenerative diseases. It has a research collaboration agreement with Janssen Pharmaceuticals, Inc. to develop regulatable gene therapy treatment using the company's proprietary riboswitch technology. The company was founded in 2015 and is headquartered in New York, New York.
Receive News & Ratings for Spark Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spark Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.